Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.90
PFE's Cash to Debt is ranked higher than
66% of the 897 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. PFE: 0.90 )
PFE' s 10-Year Cash to Debt Range
Min: 0.14   Max: 3.47
Current: 0.9

0.14
3.47
Equity to Asset 0.46
PFE's Equity to Asset is ranked higher than
57% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. PFE: 0.46 )
PFE' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.66
Current: 0.46

0.37
0.66
Interest Coverage 11.11
PFE's Interest Coverage is ranked higher than
58% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.25 vs. PFE: 11.11 )
PFE' s 10-Year Interest Coverage Range
Min: 5.24   Max: 46.41
Current: 11.11

5.24
46.41
F-Score: 4
Z-Score: 2.68
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.97
PFE's Operating margin (%) is ranked higher than
95% of the 850 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.26 vs. PFE: 26.97 )
PFE' s 10-Year Operating margin (%) Range
Min: 10.38   Max: 35.98
Current: 26.97

10.38
35.98
Net-margin (%) 20.93
PFE's Net-margin (%) is ranked higher than
94% of the 850 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.98 vs. PFE: 20.93 )
PFE' s 10-Year Net-margin (%) Range
Min: 8.65   Max: 42.65
Current: 20.93

8.65
42.65
ROE (%) 13.55
PFE's ROE (%) is ranked higher than
87% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. PFE: 13.55 )
PFE' s 10-Year ROE (%) Range
Min: 9.16   Max: 47.73
Current: 13.55

9.16
47.73
ROA (%) 6.07
PFE's ROA (%) is ranked higher than
81% of the 903 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. PFE: 6.07 )
PFE' s 10-Year ROA (%) Range
Min: 4.05   Max: 21.44
Current: 6.07

4.05
21.44
ROC (Joel Greenblatt) (%) 65.34
PFE's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.80 vs. PFE: 65.34 )
PFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 27.35   Max: 89.84
Current: 65.34

27.35
89.84
Revenue Growth (%) -3.80
PFE's Revenue Growth (%) is ranked higher than
59% of the 730 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. PFE: -3.80 )
PFE' s 10-Year Revenue Growth (%) Range
Min: -7   Max: 33.5
Current: -3.8

-7
33.5
EBITDA Growth (%) 11.80
PFE's EBITDA Growth (%) is ranked higher than
78% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. PFE: 11.80 )
PFE' s 10-Year EBITDA Growth (%) Range
Min: -6.4   Max: 41.9
Current: 11.8

-6.4
41.9
EPS Growth (%) 17.00
PFE's EPS Growth (%) is ranked higher than
82% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.00 vs. PFE: 17.00 )
PFE' s 10-Year EPS Growth (%) Range
Min: -26.8   Max: 90.5
Current: 17

-26.8
90.5
» PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PFE Guru Trades in Q4 2013

Jim Simons 7,499,841 sh (New)
Joel Greenblatt 222,280 sh (+241.71%)
Ray Dalio 110,408 sh (+102.18%)
Ronald Muhlenkamp 45,129 sh (+29.15%)
Jean-Marie Eveillard 10,186,005 sh (+23.07%)
Ruane Cunniff 11,022 sh (+5.76%)
Murray Stahl 61,605 sh (+5.01%)
John Buckingham 63,034 sh (+4.73%)
Robert Bruce 452,000 sh (+4.63%)
Diamond Hill Capital 8,339,063 sh (+4.34%)
James Barrow 61,461,287 sh (+0.93%)
Brian Rogers 12,287,115 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Mark Hillman 23,982 sh (unchged)
Michael Price 347,100 sh (unchged)
Donald Yacktman Sold Out
Louis Moore Bacon Sold Out
Ken Fisher 30,626,382 sh (-0.29%)
Bill Frels 2,570,105 sh (-0.57%)
Mario Gabelli 1,183,743 sh (-1.59%)
RS Investment Management 2,072,255 sh (-1.59%)
John Keeley 104,466 sh (-2.02%)
Dodge & Cox 65,289,814 sh (-3.14%)
HOTCHKIS & WILEY 194,900 sh (-3.56%)
NWQ Managers 10,684,522 sh (-3.88%)
Jeff Auxier 159,324 sh (-4.52%)
Pioneer Investments 9,027,655 sh (-4.71%)
Manning & Napier Advisors, Inc 1,027,334 sh (-8.19%)
Steven Cohen 103,596 sh (-8.99%)
Charles Brandes 5,767,402 sh (-9.32%)
Irving Kahn 1,899,759 sh (-24.25%)
Vanguard Health Care Fund 12,153,122 sh (-43.19%)
Jeremy Grantham 26,803,828 sh (-43.84%)
David Dreman 10,163 sh (-85.73%)
Paul Tudor Jones 46,247 sh (-95.13%)
» More
Q1 2014

PFE Guru Trades in Q1 2014

John Hussman 17,000 sh (New)
Caxton Associates 100,000 sh (New)
Louis Moore Bacon 200,452 sh (New)
Paul Tudor Jones 875,000 sh (+1792.01%)
Joel Greenblatt 1,014,808 sh (+356.54%)
Steven Cohen 295,765 sh (+185.5%)
David Dreman 11,851 sh (+16.61%)
Irving Kahn 2,112,819 sh (+11.22%)
Diamond Hill Capital 8,790,937 sh (+5.42%)
John Buckingham 65,971 sh (+4.66%)
Murray Stahl 62,855 sh (+2.03%)
Ray Dalio 112,108 sh (+1.54%)
RS Investment Management 2,080,155 sh (+0.38%)
Michael Price 347,100 sh (unchged)
Louis Moore Bacon 600,000 sh (unchged)
Robert Bruce 452,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Ruane Cunniff 11,022 sh (unchged)
Bill Frels 2,561,304 sh (-0.34%)
HOTCHKIS & WILEY 194,200 sh (-0.36%)
Charles Brandes 5,743,711 sh (-0.41%)
Ken Fisher 30,242,537 sh (-1.25%)
Mario Gabelli 1,165,574 sh (-1.53%)
Dodge & Cox 64,121,017 sh (-1.79%)
James Barrow 59,895,571 sh (-2.55%)
Pioneer Investments 8,653,390 sh (-4.15%)
John Keeley 95,893 sh (-8.21%)
Jeff Auxier 145,881 sh (-8.44%)
Ronald Muhlenkamp 41,169 sh (-8.77%)
Manning & Napier Advisors, Inc 899,181 sh (-12.47%)
NWQ Managers 9,231,207 sh (-13.6%)
Jean-Marie Eveillard 7,866,473 sh (-22.77%)
Vanguard Health Care Fund 7,276,622 sh (-40.13%)
Jeremy Grantham 6,741,800 sh (-74.85%)
Jim Simons 454,241 sh (-93.94%)
» More
Q2 2014

PFE Guru Trades in Q2 2014

Jim Simons 9,649,941 sh (+2024.41%)
Ray Dalio 393,008 sh (+250.56%)
Vanguard Health Care Fund 14,934,022 sh (+105.23%)
Joel Greenblatt 1,741,314 sh (+71.59%)
David Dreman 13,615 sh (+14.88%)
RS Investment Management 2,344,681 sh (+12.72%)
Louis Moore Bacon 225,118 sh (+12.31%)
Diamond Hill Capital 9,378,812 sh (+6.69%)
Charles Brandes 6,075,460 sh (+5.78%)
Ken Fisher 31,482,489 sh (+4.1%)
James Barrow 60,500,058 sh (+1.01%)
John Buckingham 66,601 sh (+0.95%)
Irving Kahn 2,124,489 sh (+0.55%)
Bill Frels 2,573,296 sh (+0.47%)
Murray Stahl 62,961 sh (+0.17%)
Louis Moore Bacon 1,100,000 sh (unchged)
Brian Rogers 12,287,115 sh (unchged)
Eric Mindich 3,464,000 sh (unchged)
Robert Bruce 452,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
John Hussman Sold Out
Caxton Associates Sold Out
Jeff Auxier 145,656 sh (-0.15%)
Ruane Cunniff 10,987 sh (-0.32%)
Ronald Muhlenkamp 41,019 sh (-0.36%)
Manning & Napier Advisors, Inc 882,317 sh (-1.88%)
Mario Gabelli 1,104,070 sh (-5.28%)
John Keeley 89,839 sh (-6.31%)
Pioneer Investments 7,003,706 sh (-19.06%)
Dodge & Cox 48,902,097 sh (-23.73%)
NWQ Managers 6,363,006 sh (-31.07%)
HOTCHKIS & WILEY 128,800 sh (-33.68%)
Michael Price 107,100 sh (-69.14%)
Jean-Marie Eveillard 2,303,762 sh (-70.71%)
Jeremy Grantham 349,508 sh (-94.82%)
Paul Tudor Jones 16,200 sh (-98.15%)
» More
Q3 2014

PFE Guru Trades in Q3 2014

Steven Cohen 450,000 sh (New)
Paul Tudor Jones 105,737 sh (+552.7%)
Jeremy Grantham 1,111,454 sh (+218.01%)
David Dreman 15,040 sh (+10.47%)
Diamond Hill Capital 10,195,767 sh (+8.71%)
John Keeley 97,339 sh (+8.35%)
RS Investment Management 2,437,555 sh (+3.96%)
Brian Rogers 12,737,115 sh (+3.66%)
Charles Brandes 6,257,090 sh (+2.99%)
James Barrow 62,170,881 sh (+2.76%)
Bill Frels 2,630,017 sh (+2.2%)
John Buckingham 67,724 sh (+1.69%)
Ken Fisher 31,702,495 sh (+0.7%)
Murray Stahl 63,028 sh (+0.11%)
Vanguard Health Care Fund 14,934,022 sh (unchged)
Eric Mindich 1,500,000 sh (unchged)
Robert Bruce 452,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Louis Moore Bacon 600,000 sh (unchged)
Jim Simons Sold Out
HOTCHKIS & WILEY Sold Out
Jeff Auxier 145,628 sh (-0.02%)
Ruane Cunniff 10,967 sh (-0.18%)
NWQ Managers 6,338,458 sh (-0.39%)
Dodge & Cox 47,604,980 sh (-2.65%)
Ronald Muhlenkamp 39,499 sh (-3.71%)
Manning & Napier Advisors, Inc 842,466 sh (-4.52%)
Irving Kahn 1,985,161 sh (-6.56%)
Joel Greenblatt 1,622,092 sh (-6.85%)
Mario Gabelli 1,023,581 sh (-7.29%)
Ray Dalio 295,108 sh (-24.91%)
Michael Price 47,100 sh (-56.02%)
Pioneer Investments 2,974,162 sh (-57.53%)
Louis Moore Bacon 50,000 sh (-77.79%)
Jean-Marie Eveillard 135,661 sh (-94.11%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Irving Kahn 2014-09-30 Reduce -6.56%0.59%$28.04 - $30.96 $ 30.453%1985161
Michael Price 2014-09-30 Reduce -56.02%0.22%$28.04 - $30.96 $ 30.453%47100
Jean-Marie Eveillard 2014-09-30 Reduce -94.11%0.16%$28.04 - $30.96 $ 30.453%135661
Ray Dalio 2014-09-30 Reduce -24.91%0.02%$28.04 - $30.96 $ 30.453%295108
HOTCHKIS & WILEY 2014-09-30 Sold Out 0.01%$28.04 - $30.96 $ 30.453%0
Michael Price 2014-06-30 Reduce -69.14%0.97%$29.02 - $32.4 $ 30.451%107100
NWQ Managers 2014-06-30 Reduce -31.07%0.81%$29.02 - $32.4 $ 30.451%6363006
Vanguard Health Care Fund 2014-06-30 Add 105.23%0.62%$29.02 - $32.4 $ 30.451%14934022
Dodge & Cox 2014-06-30 Reduce -23.73%0.5%$29.02 - $32.4 $ 30.451%48902097
Jean-Marie Eveillard 2014-06-30 Reduce -70.71%0.47%$29.02 - $32.4 $ 30.451%2303762
Joel Greenblatt 2014-06-30 Add 71.59%0.27%$29.02 - $32.4 $ 30.451%1741314
Charles Brandes 2014-06-30 Add 5.78%0.12%$29.02 - $32.4 $ 30.451%6075460
Ray Dalio 2014-06-30 Add 250.56%0.06%$29.02 - $32.4 $ 30.451%393008
John Hussman 2014-06-30 Sold Out 0.04%$29.02 - $32.4 $ 30.451%0
HOTCHKIS & WILEY 2014-06-30 Reduce -33.68%0.01%$29.02 - $32.4 $ 30.451%128800
Irving Kahn 2014-03-31 Add 11.22%0.98%$29.66 - $32.75 $ 30.45-3%2112819
Vanguard Health Care Fund 2014-03-31 Reduce -40.13%0.48%$29.66 - $32.75 $ 30.45-3%7276622
NWQ Managers 2014-03-31 Reduce -13.6%0.39%$29.66 - $32.75 $ 30.45-3%9231207
Joel Greenblatt 2014-03-31 Add 356.54%0.38%$29.66 - $32.75 $ 30.45-3%1014808
Jean-Marie Eveillard 2014-03-31 Reduce -22.77%0.19%$29.66 - $32.75 $ 30.45-3%7866473
John Hussman 2014-03-31 New Buy0.04%$29.66 - $32.75 $ 30.45-3%17000
Irving Kahn 2013-12-31 Reduce -24.25%2.55%$28.24 - $32.2 $ 30.45-1%1899759
Vanguard Health Care Fund 2013-12-31 Reduce -43.19%0.91%$28.24 - $32.2 $ 30.45-1%12153122
Charles Brandes 2013-12-31 Reduce -9.32%0.22%$28.24 - $32.2 $ 30.45-1%5767402
Robert Bruce 2013-12-31 Add 4.63%0.17%$28.24 - $32.2 $ 30.45-1%452000
Jean-Marie Eveillard 2013-12-31 Add 23.07%0.16%$28.24 - $32.2 $ 30.45-1%10186005
David Dreman 2013-12-31 Reduce -85.73%0.15%$28.24 - $32.2 $ 30.45-1%10163
NWQ Managers 2013-12-31 Reduce -3.88%0.12%$28.24 - $32.2 $ 30.45-1%10684522
Joel Greenblatt 2013-12-31 Add 241.71%0.11%$28.24 - $32.2 $ 30.45-1%222280
Ronald Muhlenkamp 2013-12-31 Add 29.15%0.05%$28.24 - $32.2 $ 30.45-1%45129
Ray Dalio 2013-12-31 Add 102.18%0.01%$28.24 - $32.2 $ 30.45-1%110408
Donald Yacktman 2013-12-31 Sold Out 0.01%$28.24 - $32.2 $ 30.45-1%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pfizer Inc

Diamond Hill Capital Comments on Pfizer Inc - Jul 25, 2014

Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Donald Yacktman Comments on Pfizer - Sep 09, 2013

Pfizer (PFE) was removed from the funds due to price appreciation. The company has struggled to grow over time as it has not has not been able to produce enough new drug revenues to offset major patent expirations like Lipitor. Despite the lack of growth, the stock has appreciated significantly, and we do not think it represents a good value at current prices.

From Yacktman Funds' second quarter 2013 commentary.
Check out Donald Yacktman latest stock trades

Top Ranked Articles about Pfizer Inc

Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
Legendary Investor Irving Kahn's Top Five Stocks
One of America’s oldest and most respected value investors, Irving Kahn (Trades, Portfolio), and his fund Kahn Brothers recently reported their fourth quarter holdings which boasted several hefty reductions and one sell out. Over the past quarter Kahn added one new stock, and the guru now maintains 43 stocks valued at $687 million.
Read more...
Diamond Hill Capital Comments on Pfizer Inc
Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed. Read more...
Guru Favorites Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to:Have a dividend of greater than 3%. Have a strong history of stable and increasing dividends. Maintain Guru ownership. Have a market cap of greater than $10 billion.The following four companies come from various industries and sectors of the market, but they all fit the necessary criteria needed to qualify them as dividend growers.A comparison of the companies’ historical dividend growth:AT&T (T)On June 27, AT&T declared a dividend of $0.46 per share, representing 5.20% dividend yield for the company. This dividend is payable on August 1 to shareholders of the record at the close of business on July 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 4.40%- 5-year: 2.30%- 3-year: 2.30%AT&T is a communications holding company. Its subsidiaries and affiliates are the providers of AT&T services in the U.S. and internationally. The company holds a portfolio of the nation’s fastest and most reliable 4G LTE network, wireless internet, Wi-Fi and voice and cloud-based services.AT&T’s historical revenue and net income:The analysis on AT&T reports that the company’s price is near a 5-year high, it has issued $12.6 billion in debt over the past three years and its operating income has been in loss over the past three years. On the other hand the analysis also notes that the Piotroski F-Score is high, its dividend yield is near a 2-year high and its P/E, P/S and P/B ratios are all trading at around historical lows.The Peter Lynch Chart suggests that the company is currently undervalued:AT&T has a market cap of $184.3 billion. Its shares are currently trading at around $35.51 with a P/E ratio of 10.40 and a P/S ratio of 1.50. The company had an annual average earnings growth of 4.10% over the past ten years.Lockheed Martin (LMT)On June 26, Lockheed Martin declared a dividend of $1.33 per share, representing 3.20% dividend yield for the company. This dividend is payable on Sept. 26 to shareholders of the record at the close of business on Sept. 2, 2014.

The company’s historical dividend growth is as follows:- 10-year: 20.90%- 5-year: 20.70%- 3-year: 21.90%Lockheed Martin is a security company that is principally engaged in the research, design, development, manufacture, integration, and sustainment of advanced technology systems and products. It also provides a range of management, engineering, technical, scientific, logistic, and information services.Lockheed Martin’s historical revenue and earnings growth:The analysis on Lockheed Martin reports that the company’s revenue has been in decline over the past month, its dividend yield is near a 3-year low and its price is near a 10-year high.The Peter Lynch Chart suggests that the company is currently overvalued:Lockheed Martin has a market cap of $51.02 billion. Its shares are currently trading at around $160.75 with a P/E ratio of 16.50, a P/S ratio of 1.20 and a P/B ratio of 10.50. The company had an annual average earnings growth of 9.90% over the past ten years.GuruFocus rated Lockheed Martin the business predictability rank of 3-star.Pfizer (PFE)On June 26, Pfizer declared a dividend of $0.260 per share, representing 3.40% dividend yield for the company. This dividend is payable on Sept. 3 to shareholders of the record at the close of business on Aug. 1, 2014.

The company’s historical dividend growth is as follows:- 10-year: 1.20%- 5-year: 5.80%- 3-year: 10.10%Pfizer is a global pharmaceutical firm which develops and produces medicines and vaccines for a range of conditions which include areas of immunology, inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain.Pfizer’s historical revenue and net income:The analysis on Pfizer reports that the company’s revenue has been in decline over the past year, the dividend yield is near a 5-year low, the price is near a 5-year high and its operating margin is expanding.The Peter Lynch Chart suggests that the company is currently undervalued:Pfizer has a market cap of $192.19 billion. Its shares are currently trading at around $30.13 with a P/E ratio of 9.60, a P/S ratio of 4.00 and a P/B ratio of 2.70. The company had an annual average earnings growth of 3.40% over the past ten years.GuruFocus rated Pfizer the business predictability rank of 3-star.Freeport-McMoRan Copper & Gold (FCX)On June 25, Freeport-McMoRan declared a dividend of $0.313 per share, representing 3.40% dividend yield for the company. This dividend is payable on Aug. 1 to shareholders of the record at the close of business on July 15, 2014.

The company’s historical dividend growth is as follows:- 10-year: 0.00%- 5-year: 0.00%- 3-year: 40.60%Freeport-McMoRan is a U.S.-based natural resource company with an industry leading global portfolio of mineral assets, significant oil and gas resources and a growing production profile.Freeport-McMoRan’s historical revenue and net income:The analysis on Freeport-McMoRan reports that the company’s asset growth is faster than its revenue growth and its P/S ratio is close to a 2-year low.The Peter Lynch Chart shows that the company is currently undervalued:Freeport-McMoRan Copper & Gold has a market cap of $38.43 billion. Its shares are currently trading at around $37.00 with a P/E ratio of 15.10, a P/S ratio of 1.80 and a P/B ratio of 1.50. The dividend yield for the company is currently sitting at 3.40%.To view a complete list of high yielding dividend stocks found among the gurus’ portfolios, click here.

Try a free 7-day premium membership. Read more...
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014?
Pfizer (PFE) will release its first quarter 2014 earnings report before the opening bell on Monday, May 5, 2014. Since the company has posted higher than expected earnings over the past three quarters, analysts and investors are looking for the pharmaceutical giant to beat the Street’s estimates once again. Read more...
Pfizer and Lockheed Martin Top Dividend Growers of the Week
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
AT&T and Pfizer Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized five companies as dividend growers. In order to be qualified for this list, the company had to:
Read more...
Top Five Guru-Held Health Care Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the third quarter, the following five health care companies are held by the largest number of gurus. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.80
PFE's P/E(ttm) is ranked higher than
91% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.60 vs. PFE: 18.80 )
PFE' s 10-Year P/E(ttm) Range
Min: 7.67   Max: 200.11
Current: 18.8

7.67
200.11
P/B 2.50
PFE's P/B is ranked higher than
77% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. PFE: 2.50 )
PFE' s 10-Year P/B Range
Min: 1.32   Max: 4.55
Current: 2.5

1.32
4.55
P/S 3.90
PFE's P/S is ranked higher than
71% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.92 vs. PFE: 3.90 )
PFE' s 10-Year P/S Range
Min: 1.72   Max: 6.3
Current: 3.9

1.72
6.3
PFCF 12.60
PFE's PFCF is ranked higher than
98% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 12.60 )
PFE' s 10-Year PFCF Range
Min: 5.02   Max: 35.16
Current: 12.6

5.02
35.16
EV-to-EBIT 14.50
PFE's EV-to-EBIT is ranked higher than
89% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. PFE: 14.50 )
PFE' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 64.3
Current: 14.5

6.6
64.3
PEG 2.09
PFE's PEG is ranked higher than
90% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 2.09 )
PFE' s 10-Year PEG Range
Min: 1.16   Max: 18.74
Current: 2.09

1.16
18.74
Shiller P/E 17.60
PFE's Shiller P/E is ranked higher than
94% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 141.81 vs. PFE: 17.60 )
PFE' s 10-Year Shiller P/E Range
Min: 8.49   Max: 39.64
Current: 17.6

8.49
39.64
Current Ratio 2.86
PFE's Current Ratio is ranked higher than
75% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. PFE: 2.86 )
PFE' s 10-Year Current Ratio Range
Min: 0.98   Max: 3.18
Current: 2.86

0.98
3.18
Quick Ratio 2.54
PFE's Quick Ratio is ranked higher than
78% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. PFE: 2.54 )
PFE' s 10-Year Quick Ratio Range
Min: 0.74   Max: 2.86
Current: 2.54

0.74
2.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.40
PFE's Dividend Yield is ranked higher than
90% of the 517 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. PFE: 3.40 )
PFE' s 10-Year Dividend Yield Range
Min: 1.54   Max: 10.4
Current: 3.4

1.54
10.4
Dividend Payout 0.63
PFE's Dividend Payout is ranked higher than
96% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. PFE: 0.63 )
PFE' s 10-Year Dividend Payout Range
Min: 0.12   Max: 8.21
Current: 0.63

0.12
8.21
Dividend growth (3y) 10.10
PFE's Dividend growth (3y) is ranked higher than
84% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. PFE: 10.10 )
PFE' s 10-Year Dividend growth (3y) Range
Min: -14.7   Max: 22.6
Current: 10.1

-14.7
22.6
Yield on cost (5-Year) 4.51
PFE's Yield on cost (5-Year) is ranked higher than
89% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. PFE: 4.51 )
PFE' s 10-Year Yield on cost (5-Year) Range
Min: 2.04   Max: 13.79
Current: 4.51

2.04
13.79
Share Buyback Rate 5.10
PFE's Share Buyback Rate is ranked higher than
92% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. PFE: 5.10 )
PFE' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -19
Current: 5.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.91
PFE's Price/DCF (Projected) is ranked higher than
96% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.94 vs. PFE: 0.91 )
PFE' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 10.35
Current: 0.91

0.53
10.35
Price/Median PS Value 1.15
PFE's Price/Median PS Value is ranked higher than
77% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.31 vs. PFE: 1.15 )
PFE' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 4.51
Current: 1.15

0.52
4.51
Price/Peter Lynch Fair Value 1.83
PFE's Price/Peter Lynch Fair Value is ranked higher than
92% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PFE: 1.83 )
PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.9   Max: 13.85
Current: 1.83

0.9
13.85
Earnings Yield (Greenblatt) 6.90
PFE's Earnings Yield (Greenblatt) is ranked higher than
89% of the 878 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. PFE: 6.90 )
PFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 15.2
Current: 6.9

1.6
15.2
Forward Rate of Return (Yacktman) 15.93
PFE's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.06 vs. PFE: 15.93 )
PFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.6   Max: 20.5
Current: 15.93

7.6
20.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany, PFIZ34.Brazil, PFE.Mexico, PFE.Argentina, PFE.Chile
Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its global resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. They managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products primarily prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension), erectile dysfunction, and genitourinary, major depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes worldwide revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its global biopharmaceutical businesses, they promote its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its major products. The Company is subject to extensive regulation by national, state and local agencies in the countries in which they do business.
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Guru Ken Fisher’s Top Five Quarterly Stocks Nov 16 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Activist Bill Ackman Buys Big Stake In Animal Healthcare Company Zoetis Nov 12 2014 
The Importance of Capital Intensity and Thoughts From Einhorn Oct 31 2014 
Johnson & Johnson Fairly Valued – I Will Bet on It Oct 30 2014 
My 5 Favorite Stocks With Dividend Growth Of The Week Oct 27 2014 
Guru Stocks at 52-Week Lows: GOOG, PFE, UN, E, MTU Oct 20 2014 
10 Stocks With The Highest Share Buyback Volume In 2014 Oct 03 2014 
A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 
The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 


More From Other Websites
Do The IMPROVE-IT Results Offer Promise For Anacetrapib, Another Merck Heart Drug? Nov 21 2014
New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
FDA approves new, hard-to-abuse hydrocodone pill Nov 20 2014
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal Nov 18 2014
AstraZeneca fleshes out standalone strategy Nov 18 2014
TRUMENBA® (Meningococcal Group B Vaccine) is Now Available Nov 18 2014
AstraZeneca’s Soriot Asks for Patience as Pfizer Return Looms Nov 18 2014
Neil Woodford: there's a 50/50 chance Pfizer will come back for AstraZeneca Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
TRUMENBA® (Meningococcal Group B Vaccine) is Now Available Nov 18 2014
Neil Woodford says belief in independent AstraZeneca 'even stronger' Nov 18 2014
Neil Woodford says belief in independent AstraZeneca "even stronger" Nov 18 2014
Neil Woodford says belief in independent AstraZeneca "even stronger" Nov 18 2014
AstraZeneca trumpets progress in cancer, other drugs Nov 18 2014
AstraZeneca trumpets progress in cancer, other drugs Nov 18 2014
Aussie pharma group taking on Pfizer Nov 17 2014
Pfizer sues Aussie pharma group's US arm Nov 17 2014
Allergan Sides With More Aggressive Dealmaker By Picking Actavis Over Valeant Nov 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK